54665-92-8

Basic information

• Product Name: 4,7-DICHLORO-2-PHENYL-QUINAZOLINE
• Synonyms: 4,7-DICHLORO-2-PHENYL-QUINAZOLINE;Quinazoline, 4,7-dichloro-2-phenyl-
• CAS NO: 54665-92-8
• Molecular Formula: C₁₄H₈Cl₂N₂
• Molecular Weight: 275.13
• Mol File: 54665-92-8.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 332.6 °C at 760 mmHg
• Flash Point: 185.1 °C
• Appearance: /
• Density: 1.381 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4,7-DICHLORO-2-PHENYL-QUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4,7-DICHLORO-2-PHENYL-QUINAZOLINE(54665-92-8)
• EPA Substance Registry System: 4,7-DICHLORO-2-PHENYL-QUINAZOLINE(54665-92-8)

Safety Data

• Hazardous Substances Data: 54665-92-8(Hazardous Substances Data)

Usage

General Description

4,7-Dichloro-2-phenyl-quinazoline is a chemical compound with the molecular formula C15H8Cl2N2. It is a quinazoline derivative, which is a heterocyclic aromatic compound. 4,7-Dichloro-2-phenyl-quinazoline has two chlorine atoms and one phenyl group attached to the quinazoline ring. It has potential applications in the field of medicinal chemistry, particularly in the development of new drugs and pharmaceuticals. The specific properties and uses of 4,7-Dichloro-2-phenyl-quinazoline will depend on the specific research and development purposes for which it is being used.

InChI:InChI=1S/C14H8Cl2N2/c15-10-6-7-11-12(8-10)17-14(18-13(11)16)9-4-2-1-3-5-9/h1-8H

Upstream product

• 89-77-0 2-Amino-4-chlorobenzoic acid 
• 98-88-4 benzoyl chloride 
• 7033-52-5 7-chloro-2-phenyl-4H-benzo[d][1,3]oxazin-4-one 
• 7012-94-4 7-chloro-5-methyl-2-phenylquinazolin-4(3H)-one 

Relevant articles and documents

Design, Synthesis, and Pharmacological Characterization of N-(4-(2 (6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)yl)ethyl)phenyl)quinazolin-4-amine Derivatives: Novel Inhibitors Reversing P-Glycoprotein-Mediated Multidrug Resistance

P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a principal obstacle for successful cancer chemotherapy. A novel P-gp inhibitor with a quinazoline scaffold, 12k, was considered to be the most promising for in-depth study. 12k possessed high potency (EC50 = 57.9 ± 3.5 nM), low cytotoxicity, and long duration of activity in reversing doxorubicin (DOX) resistance in K562/A02 cells. 12k also boosted the potency of other MDR-related cytotoxic agents with different structures, increased accumulation of DOX, blocked P-gp-mediated Rh123 efflux, and suppressed P-gp ATPase activity in K562/A02 MDR cells. However, 12k did not have any effects on CYP3A4 activity or P-gp expression. In particular, 12k had a good half-life and oral bioavailability and displayed no influence on DOX metabolism to obviate the side effects closely related to increased plasma concentrations of cytotoxic agents in vivo.